|Hyperalgesia - Pipeline Review, H1 2014: New Research Report Available at ...|
This report provides comprehensive information on the therapeutic development for Hyperalgesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and ...
DigitalJournal.com - Thu, 17 Jul 2014 07:21
|Targiniq ER painkiller pill designed to prevent abuse, gets FDA approval|
... of its 'street marketability.'" The FDA still required Purdue Pharma to conduct postmarketing studies that would evaluate the serious risks associated with long term use of the drug including overdose, heightened sensitivity to pain or hyperalgesia ...
Tech Times - Sat, 26 Jul 2014 20:22
|Study shows mind-control techniques can help manage chronic pain|
In a study led by Dr Tim Salomons, healthy participants were given five minute spells of cognitive behavioural therapy (CBT) before having eight, hour-long sessions of heat applied to their forearm to evoke pain. This created areas of secondary ...
Reading Post - Fri, 18 Jul 2014 03:30
|New hope for chronic pain sufferers|
Medical Xpress - Fri, 18 Jul 2014 05:00
|Positive thinking helps manage pain|
Yahoo News UK - Fri, 18 Jul 2014 08:00
|Think Positive to Reduce Pain: Study|
Speaking about the findings of the study, Dr Tim Salomons, lead researcher from the University of Reading, said, "Of the 34 participants given secondary hyperalgesia, half were trained to control negative thoughts related to the pain, the other half ...
International Business Times AU - Mon, 21 Jul 2014 23:56
|FDA approves ER oxycodone formulation designed to deter abuse|
Postmarketing studies of the drug, as required by the FDA, will evaluate the potential for misuse, abuse, hyperalgesia, addiction, overdose and death over a longer follow-up (beyond 12 weeks). Additionally, the FDA is requiring postmarketing studies to ...
Healio - Wed, 23 Jul 2014 14:56
|FDA approves Targiniq ER, extended-release oxycodone, to treat severe pain|
The Global Dispatch - Wed, 23 Jul 2014 17:25
|FDA Approves Abuse-Deterrent Oxycodone/Naloxone Combo|
The FDA is requiring postmarketing studies to assess the risks for misuse, abuse, hyperalgesia, addiction, overdose and death with Targiniq ER, and to further assess the effects of the abuse-deterrent features on the risk for abuse. "In addition ...
Medscape - Wed, 23 Jul 2014 15:30
|Pill Man: One man's fight to overcome opiate addiction|
While it is unclear whether Huntley developed it, there is a condition known as Opioid-Induced hyperalgesia, a condition through which some people taking opioids develop an increased sensitivity to pain. In short, the pills can end up having the ...
Worcester Mag - Thu, 17 Jul 2014 03:04
|Shares in Addex jump on positive results in mice of nicotine treatment|
Results of the preclinical study found Addex' drug ADX71441 helped reverse some of the somatic signs of withdrawal in nicotine-dependent mice and at the highest dose also reversed increased sensitivity to pain known as hyperalgesia. Even though the ...
Reuters UK - Thu, 10 Jul 2014 02:00